AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

AMZN

210.15

+2.4%↑

TSLA

380.77

+3.53%↑

HD

330.77

+3.02%↑

TM

210.24

+2.62%↑

MCD

308.25

-0.38%↓

Search

Cavco Industries Inc

Slēgts

SektorsCikliskās patēriņa

473.06 3.46

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

457.22

Max

485.3

Galvenie mērījumi

By Trading Economics

Ienākumi

-8.3M

44M

Pārdošana

24M

581M

P/E

Sektora vidējais

22.22

33.36

EPS

5.58

Peļņas marža

7.585

Darbinieki

7,000

EBITDA

-25M

48M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+24.96% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 21. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.2B

4B

Iepriekšējā atvēršanas cena

469.6

Iepriekšējā slēgšanas cena

473.06

Ziņu noskaņojums

By Acuity

50%

50%

140 / 338 Rangs Consumer cyclical

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Cavco Industries Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. marts 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026. g. 23. marts 22:55 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026. g. 23. marts 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026. g. 23. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026. g. 23. marts 23:37 UTC

Tirgus saruna

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026. g. 23. marts 22:40 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026. g. 23. marts 22:23 UTC

Tirgus saruna

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026. g. 23. marts 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026. g. 23. marts 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026. g. 23. marts 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026. g. 23. marts 22:08 UTC

Tirgus saruna

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026. g. 23. marts 21:10 UTC

Galvenie ziņu notikumi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna
Peļņas
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Cavco Industries Inc Prognoze

Cenas mērķis

By TipRanks

24.96% augšup

Prognoze 12 mēnešiem

Vidējais 575 USD  24.96%

Augstākais 575 USD

Zemākais 575 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cavco Industries Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

512.41 / N/AAtbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

140 / 338 Rangs Cikliskās patēriņa

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Cavco Industries Inc

Cavco Industries, Inc. designs, produces, and retails factory-built homes primarily in the United States. It operates in two segments, Factory-Built Housing and Financial Services. The company markets its factory-built homes under the Cavco, Fleetwood, Palm Harbor, Nationwide, Fairmont, Friendship, Chariot Eagle, Destiny, Commodore, Colony, Pennwest, R-Anell, Manorwood, MidCountry, and Solitaire brands. It produces park model RVs; vacation cabins; and factory-built commercial structures, including apartment buildings, condominiums, hotels, workforce housing, schools, and housing for the United States military troops. In addition, the company produces various modular homes, which include single and multi-section ranch, split-level, and Cape Cod style homes, as well as two- and three-story homes, and multi-family units. Further, it provides conforming and non-conforming mortgages and home-only loans to purchasers of various brands of factory-built homes sold by company-owned retail stores, as well as various independent distributors, builders, communities, and developers. Additionally, the company offers property and casualty insurance to owners of manufactured homes. It distributes its products through a network of independent and company-owned retailers, planned community operators, and residential developers. Cavco Industries, Inc. was founded in 1965 and is headquartered in Phoenix, Arizona.
help-icon Live chat